![Naycho Tecnology](/dam/jcr:e02acdea-33fa-44ae-89c7-b9cbc272b874/Naycho%20Tecnology.jpg)
Foresight and determination are the two driving levers that guided IBSA in making a strategic and significant choice: investing in Southern Italy by launching a network of valuable partnerships and opening, in the heart of Campania, one of three R&D labs, active on the most advanced frontiers of biomedical research.
It’s IBSA Italy’s centre in Ariano Irpino, in the province of Avellino, located within a hub of excellence in the field of scientific research. It’s here that IBSA researchers carry out some of the most delicate phases concerning the production of drugs: the development of preclinical in vitro and in vivo studies, essential to determine the efficacy and safety of the products.
The other flagship are the partnerships established and consolidated in recent years with the entrepreneurial research and development realities of Campania. In fact, the strong bond that the company built over the years with the local territory generated two major collaborations with the University of Naples Federico II and with the University of Campania “Luigi Vanvitelli”; in turn, these projects promoted the development of the NAHYCO® Hybrid Technology – an innovative way to obtain high- and low-molecular weight hybrid formulations of hyaluronic acid, which allows to increase the dosage and optimise the properties for intra-articular and intradermal use.